[Current advances and issues in selective estrogen receptor modulator (SERM) treatment].
The use of selective estrogen receptor modulators (SERMs) was limited at first to relatively young women and was overestimated for the risk of venous thromboembolism (VTE) due to their estrogen-like effects. Ten years of clinical experience with the SERMs in Japan suggest that they can be used without concern for VTE and are efficacious in older women. Thus, the SERMs are now being recognized as agents readily available for clinical use. Furthermore, unlike the bisphosphonates, their physiological hormone-like effects have led to their widespread use in clinical settings. Future issues in treatment with the SERMs include generation of evidence for their efficacy in improving bone quality as well as for their efficacy in the oldest population. Given their excellent, well-balanced efficacy and safety profile as well as their convenience, however, the SERMs are thought likely to become further established as the standard of care in osteoporosis and other diseases.